The Growing Appetite for Obesity Drugs

Dec 1, 2023

Learn about the growing popularity and market potential of obesity drugs, their role in addressing the obesity epidemic, challenges of access and insurance coverage, development of oral medications, duration of treatment, market potential compared to diabetes drugs, and the cultural impact of weight loss medications.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

GLP-1's surprising weight loss effect

GLP-1 drugs were initially designed for diabetes treatment but cause significant weight loss as a side effect.
This weight loss effect is now the primary focus for treating obesity.

INSIGHT

Obesity: A Market Need and Patient Demand

The obesity epidemic represents a significant unmet need in the market, with 40% of the US population affected.
Unlike other medications, patients actively seek GLP-1 drugs, creating unique market dynamics.

INSIGHT

Key Players and Increased Efficacy

Novo Nordisk and Eli Lilly are the two main players in the GLP-1 market.
Newer GLP-1 drugs show significantly better efficacy, with patients losing substantial weight, capturing public attention.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

The market for GLP-1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in health care? Elif Korkmaz, who covers Health Care Specialist Sales, sits down with Chris Schott, Senior Analyst covering U.S. Diversified Biopharma, and Richard Vosser, Head of European Pharma & Biotech, to discuss the latest developments in this space.

This episode was recorded on Wednesday, November 29th, 2023.

This communication is provided for information purposes only. Please visit www.jpmm.com/research/disclosures for important disclosures. JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively, J.P. Morgan) normally make a market and trade as principal in securities, other financial products and other asset classes that may be discussed in this communication.

This communication has been prepared based upon information from sources believed to be reliable, but J.P. Morgan does not warrant its completeness or accuracy except with respect to any disclosures relative to J.P. Morgan and/or its affiliates and an analyst's involvement with any company (or security, other financial product or other asset class) that may be the subject of this communication. Any opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This communication is not intended as an offer or solicitation for the purchase or sale of any financial instrument. J.P. Morgan Research does not provide individually tailored investment advice. Any opinions and recommendations herein do not take into account individual circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies. You must make your own independent decisions regarding any securities, financial instruments or strategies mentioned or related to the information herein. Periodic updates may be provided on companies, issuers or industries based on specific developments or announcements, market conditions or any other publicly available information. However, J.P. Morgan may be restricted from updating information contained in this communication for regulatory or other reasons. This communication may not be redistributed or retransmitted, in whole or in part, or in any form or manner, without the express written consent of J.P. Morgan. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute or retransmit the contents and information contained in this communication without first obtaining express permission from an authorized officer of J.P. Morgan.